Semaglutide vs Tirzepatide
Bottom line
Both are FDA-approved, once-weekly injectable incretin drugs for type 2 diabetes and obesity, and both belong to the Metabolic & GLP-1 class. Tirzepatide (a dual GIP/GLP-1 agonist) produced greater weight loss and glycemic improvement than Semaglutide in head-to-head trials, while semaglutide has the longer track record, the strongest cardiovascular-outcomes evidence, and an oral option. Choice between them is a clinical decision based on goals, tolerability, comorbidities, and access.
At a glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| Class | GLP-1 receptor agonist (mono-agonist) | Dual GIP/GLP-1 receptor agonist |
| Primary use | Type 2 diabetes; obesity; cardiovascular risk reduction | Type 2 diabetes; obesity; obstructive sleep apnea |
| Evidence level | Approved — SUSTAIN, STEP, SELECT Phase 3 programs | Approved — SURPASS, SURMOUNT Phase 3 programs |
| Typical weight loss | ~14.9% at 2.4 mg over 68 wks (STEP-1); −13.7% in SURMOUNT-5 head-to-head | ~15–20.9% over 72 wks (SURMOUNT-1); −20.2% in SURMOUNT-5 head-to-head |
| Half-life | ~7 days (~160 h) | ~5 days |
| Route | Subcutaneous (Ozempic, Wegovy) · Oral (Rybelsus; oral Wegovy 25 mg) | Subcutaneous only (Mounjaro, Zepbound) |
| Legal / FDA status | FDA-approved — Ozempic (T2D, 2017), Rybelsus (oral T2D, 2019), Wegovy (obesity 2021; CV risk 2024; MASH 2025), oral Wegovy 25 mg (obesity, Dec 2025) | FDA-approved — Mounjaro (T2D, 2022), Zepbound (obesity 2023; OSA 2024) |
Key Differences
- Mechanism. Semaglutide activates a single incretin receptor (GLP-1). Tirzepatide is a dual agonist hitting both GIP and GLP-1; the added GIP arm is hypothesized to amplify weight loss and improve GI tolerability, though the GIP contribution in humans is still being characterized.
- Head-to-head weight loss (obesity, no diabetes). In SURMOUNT-5 (Phase 3b, open-label, 751 adults, 72 weeks), tirzepatide produced −20.2% mean body-weight change versus −13.7% for semaglutide 2.4 mg — a 6.5-percentage-point difference. About 19.7% of the tirzepatide group lost ≥30% of body weight versus 6.9% on semaglutide.
- Head-to-head in diabetes. In SURPASS-2 (40 weeks, add-on to metformin), all three tirzepatide doses achieved greater HbA1c and weight reductions than semaglutide 1 mg; the highest tirzepatide dose lowered HbA1c by ~2.30% vs ~1.86% for semaglutide.
- Cardiovascular outcomes. Semaglutide has the more mature CV-outcomes evidence: the SELECT trial showed ~20% reduction in major adverse cardiovascular events, supporting a 2024 label expansion. Tirzepatide’s dedicated CV outcomes data (SURPASS-CVOT / SURMOUNT-MMO) is still maturing.
- Route and formulation. Semaglutide offers oral forms (Rybelsus for T2D, and — since Dec 2025 — oral Wegovy 25 mg for obesity, the first oral GLP-1 for weight loss); tirzepatide is injection-only. Semaglutide’s half-life (~7 days) is slightly longer than tirzepatide’s (~5 days); both are dosed once weekly.
- Other approved indications. Tirzepatide is also approved for obstructive sleep apnea (Zepbound, 2024). Semaglutide carries the cardiovascular risk-reduction indication, was approved in 2025 for MASH with liver fibrosis (first GLP-1 for that use), and has additional data in chronic kidney disease (FLOW).
- Track record. Semaglutide has been marketed longer (since 2017) with broader real-world experience; tirzepatide is newer (since 2022) but has shown superior efficacy in the available comparisons.
- Shared class profile. Both carry GI side effects (nausea, diarrhea, vomiting, constipation), a boxed warning for thyroid C-cell tumors (rodent data), and risks of gallbladder disease, rare pancreatitis, and lean-mass loss with rapid weight reduction. Both saw legal compounding wind down in 2025 after shortages resolved (see Regulatory & Legal Status).
Which Is Right For Whom
- Maximum weight loss or glycemic control has favored tirzepatide in direct trials, but this is a prescribing decision that must weigh tolerability, comorbidities, and cost.
- Established cardiovascular disease is where semaglutide currently has the strongest outcomes evidence (SELECT).
- Preference for an oral option points to semaglutide (Rybelsus, T2D only); tirzepatide has no oral form.
- Obstructive sleep apnea with obesity is a specific indication where tirzepatide (Zepbound) is approved.
- Both are prescription drugs: indication, dose, titration, and monitoring should be set by a clinician. Neither is a “cycle” compound — they are chronic therapies, and stopping typically leads to weight regain. See Fat Loss and Metabolic & GLP-1 for class context, and Evidence Grading Explained for what the evidence tiers mean.
Not medical advice — See Disclaimer.
References
- Aronne L.J. et al. (2025). “Tirzepatide vs Semaglutide for the Treatment of Obesity” (SURMOUNT-5). New England Journal of Medicine — −20.2% vs −13.7% at 72 weeks.
- Frías J.P. et al. (2021). “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes” (SURPASS-2). New England Journal of Medicine.
- Wilding J.P.H. et al. (2021). “Once-Weekly Semaglutide in Adults with Overweight or Obesity” (STEP-1). New England Journal of Medicine.
- Jastreboff A.M. et al. (2022). “Tirzepatide Once Weekly for the Treatment of Obesity” (SURMOUNT-1). New England Journal of Medicine.
- Lincoff A.M. et al. (2023). “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes” (SELECT). New England Journal of Medicine.
← Stacks · Home Educational information only — not medical advice. See Disclaimer.